Cellectar Biosciences Statistics
Want to see CLRB full AI Analyst Report?
Cellectar Biosciences (CLRB) Stock Statistics & Valuation Metrics
Total Valuation
Cellectar Biosciences has a market cap or net worth of $9.24M. The enterprise value is $9.08M.
- Market Cap
- $9.24M
- Enterprise Value
- $9.08M
Share Statistics
Cellectar Biosciences has 10,039,183 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,039,183
- Owned by Insiders
- 0.91%
- Owned by Institutions
- 40.23%
Financial Efficiency
Cellectar Biosciences’s return on equity (ROE) is -2.20 and return on invested capital (ROIC) is -222.48%.
- Return on Equity (ROE)
- -2.20
- Return on Assets (ROA)
- -1.45
- Return on Invested Capital (ROIC)
- -222.48%
- Return on Capital Employed (ROCE)
- -2.25
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.98M
- Employee Count
- 11
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cellectar Biosciences is -0.26. Cellectar Biosciences’s PEG ratio is -0.00.
- PE Ratio
- -0.26
- PS Ratio
- 0.00
- PB Ratio
- 0.74
- Price to FCF
- -0.39
- Price to Operating Cash Flow
- -0.67
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Cellectar Biosciences had revenue of 0 and earned -21.79M in profits. Earnings per share was -8.35.
- Revenue
- 0
- Gross Profit
- -213.60K
- Operating Income
- -22.98M
- Pretax Income
- -21.79M
- Net Income
- -21.79M
- EBITDA
- -21.58M
- Earnings Per Share (EPS)
- -8.35
Cash Flow
In the last 12 months, operating cash flow was -24.61M and capital expenditures -9,259, giving a free cash flow of -24.62M billion.
- Operating Cash Flow
- -24.61M
- Free Cash Flow
- -24.62M
- Free Cash Flow per Share
- -1.41
Dividends & Yields
Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -269.42%
- Earnings Yield
- -162.64%
Stock Price Statistics
- Beta
- 1.17
- 52-Week Price Change
- -68.49%
- 50-Day Moving Average
- 1.63
- 200-Day Moving Average
- 2.51
- Relative Strength Index (RSI)
- 26.34
- Average Volume (3m)
- 96.60K
Important Dates
Cellectar Biosciences upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Cellectar Biosciences as a current ratio of 2.96, with Debt / Equity ratio of 4.13%
- Current Ratio
- 2.96
- Quick Ratio
- 2.96
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.59
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Cellectar Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cellectar Biosciences EV to EBITDA ratio is 0.53, with an EV/FCF ratio of 0.57.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.53
- EV to Free Cash Flow
- 0.57
- EV to Operating Cash Flow
- 0.57
Balance Sheet
Cellectar Biosciences has $24.58M in cash and marketable securities with $1.53M in debt, giving a net cash position of $23.05M billion.
- Cash & Marketable Securities
- $24.58M
- Total Debt
- $1.53M
- Net Cash
- $23.05M
- Net Cash Per Share
- $2.30
- Tangible Book Value Per Share
- $1.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Cellectar Biosciences is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $10.00
- Price Target Upside
- 986.96% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 66.06%
Scores
- Smart Score
- ―
- AI Score
- 46

